


## PHARMACEUTICAL 2022

## Equillium Inc. Rank 212 of 466





## PHARMACEUTICAL 2022

## Equillium Inc. Rank 212 of 466

The relative strengths and weaknesses of Equillium Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Equillium Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 72% points. The greatest weakness of Equillium Inc. is the variable Net Income, reducing the Economic Capital Ratio by 19% points.

The company's Economic Capital Ratio, given in the ranking table, is 145%, being 67% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	83,370
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	8,915
Liabilities, Non-Current	1,235
Other Assets	1,798
Other Compr. Net Income	159
Other Expenses	0
Other Liabilities	8,750
Other Net Income	-1,266
Other Revenues	0
Property and Equipment	237
Research and Development	26,379
Selling, General and Administrative Expense	11,407

Output Variable	Value in 1000 USD
Assets	85,405
Liabilities	18,900
Expenses	37,786
Revenues	0
Stockholders Equity	66,505
Net Income	-39,052
Comprehensive Net Income	-38,972
Economic Capital Ratio	145%

